Medicinal properties of milk thistle with special reference to silymarinñ an overview

Natural Product Radiance

Volumn 7, Issue 2, 2008, Pages 182-192

  Das, Subir Kumar ^a   Mukherjee, Sukhes ^a   Vasudevan, D M ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti carcinogenic; Anti fibrotic; Anti inflammatory; Anti tumourogenesis; Antioxidant; Hepatoprotection; Hepatotoxicity; Milk thistle; Silibinin; Silybin; Silybum marianum; Silymarin

Indexed keywords

SILYBUM MARIANUM;

EID: 78549283151     PISSN: 0972592X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. Schuppan D, Jia J, Brinkhaus B and Hahn EG, Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology, 1999, 30, 1099-1104.
2. Luper S, A review of plants used in the treatment of liver disease: part 1, Altern Med Rev, 1998, 3(6), 410-421.
3. http://www.stevenfoster.com/education/monograph/milkthistle.html.
4. Valenzuela A and Garrido A, Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin, Biol Res, 1994, 27, 105-112.
5. Pradhan SC and Girish C, Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine, Indian J Med Res, 2006, 124, 491-504.
6. Lee DY and Liu Y, Molecular Structure and Stereochemistry of Silybin A, Silybin B, Isosilybin A and Isosilybin B, Isolated from Silybum marianum (Milk thistle), J Nat Prod, 2003, 66(9), 1171-1174.
7. Saller R, Meier R and Brignoli R, The use of silymarin in the treatment of liver diseases, Drugs, 2001, 61(14), 2035-2063.
8. Monograph: Silybum marianum (Milk Thistle), Altern Med Rev, 1999, 4(4), 272-274.
9. Flora K, Hahn M, Rosen H and Benner K, Milk thistle (Silybum marianum) for the therapy of liver disease, Am J Gastroenterol, 1998, 93(2), 139-143.
10. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO and Schuppan D, Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats, Hepatology, 1997, 26(3), 643-649.
11. Morazzoni P, Montalbetti A, Malandrino S and Pifferi G, Comparative pharmacokinetics of silipide and silymarin in rats, Eur J Drug Metab Pharmacokinet, 1993, 18(3), 289-297.
12. Weyhenmeyer R, Mascher H and Birkmayer J, Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereo specific assay, Int J Clin Pharmacol Ther Toxicol, 1992, 30(4), 134-138.
13. Gunaratna C and Zhang T, Application of liquid chromatography-electrospray ionization-ion trap mass spectrometry to investigate the metabolism of silibinin in human liver microsomes, J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 794(2), 303-310.
14. Vailati A, Aristia L, Sozze E, Milani F, Inglese V and Galenda P, Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis, Fitoterapia, 1993, 64, 219-231.
15. Barzaghi N, Crema F, Gatti G, Pifferi G and Perucca E, Pharmacokinetic studies on Idb 1016, a silybin phosphatidylcholine complex, in healthy human subjects, Eur J Drug Meta Pharmacokinet, 1990, 15, 333-338.
16. Berger Jose, Kowdley Kris V, Is Silymarin Hepatoprotective in alcoholic liver disease? J Clinic Gastroent, 2003, 37(4), 278-279.
17. Lettéron P, Labbe G, Degott C, Berson A, Fromenty B, Delaforge M, Larrey D and Pessayre D, Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant, Biochem Pharmacol, 1990, 39(12), 2027-2034.
18. Valenzuela A, Aspillaga M, Vial S and Guerra R, Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat, Planta Med, 1989, 55, 420-422.
19. Nencini C, Giorgi G and Micheli L, Protective effect of silymarin on oxidative stress in rat brain, Phytomedicine, 2007, 14(2-3), 129-135.
20. Dehmlow C, Murawski N and de Groot H, Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells, Life Sci, 1996, 58(18), 1591-1600.
21. Filipe PM, Fernandes AC, Silva JN, Freitas JP and Manso CF, Effect of silibinin on oxidative damage of blood constituents, CR Séances Soc Biol Fil, 1997, 191(5-6), 821-835.
22. Mira L, Silva M and Manso C F, Scavenging of reactive oxygen species by silibinin dihemisuccinate, Biochem Pharmacol, 1994, 48(4), 753-759.
23. Feher J, Lang I, Nekam K, Csomos G, Muzes G and Deak G, Effect of silibinin on the activity and expression of superoxide dismutase in lymphocytes from patients with chronic alcoholic liver disease, Free Radic Res Commun, 1987, 3(6), 373-377.
24. Sharma A, Chakraborti KK and Handa SS, Anti-hepatotoxic activity of some Indian herbal formulations as compared to silymarin, Fitoterapia, 1991, 62, 229-235.
25. Muriel P and Mourelle M, The role of membrane composition in ATPase activities of cirrhotic rat liver: effect of silymarin, J Appl Toxicol, 1990, 10(4), 281-284.
26. Favari L and Perez-Alvarez V, Comparative effects of colchicines and silymarin on CCl4 -chronic liver damage in rats, Arch Med Res, 1997, 28, 11-17.
27. Pulla Reddy A and Lokesh BR, Effect of curcumin and eugenol on iron-induced hepatic toxicities in rats, Toxicology, 1996, 107, 39-45.
28. Bhattacharya A, Ramanathan M, Ghosal and Bhattacharya SK, Effect of Withania somnifera glycowithanolides on iron induced heopatotoxicity in rats, Phytother Res, 2000, 14, 568-570.
29. Srivastava S, Srivastava AK, Srivastava S, Patnaik GK and Dhawan BN, Effect of picroliv and silymarin on liver regeneration in rats, Indian J Pharmacol, 1994, 26, 19-22.
30. Schopen RD, Lange OK and Panne C, Searching for a new therapeutic principle. Experience with hepatic therapeutic agent legalon, Medical Welt, 1969, 20, 888-893.
31. Saratikov AS, Vengerovskii AI and Sedykh IM, The correction with hepatic protectors of structural metabolic disorders in the liver in D-galactosamine poisoning, Farmakol Toksikol, 1990, 53(2), 38-40.
32. Choppin J and Desplaces A, The effects of silybin on experimental phalloidine poisoning, Arzneimittelforschung, 1978, 28, 636-641.
33. Laekeman G, De Coster S and De Meyer K, St. Mary's Thistle: an overview, J Pharm Belg, 2003, 58(1), 28-31.
34. Svendsen BS, Gjellestad A, Eivindson G, Berentsen G and Jacobsen D, Serious mushroom poisoning by Cortinarius and Amanita virosa, Tidsskr Nor Laegeforen, 2002, 122(8), 777-780.
35. Saraswat B, Visen PKS, Patnaik GK and Dhawan BN, Effect of andrographolide against galactosamine-induced hepatotoxicity, Fitoterapia, 1995, 66, 415-420.
36. Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R and Tiegs G, Silibinin protects mice from T cell-dependent liver injury (small star, filled), J Hepatol, 2003, 39(3), 333-340.
37. Vogel G and Trost W, Zur anti-phalloidinaktivität der silymarine silybin und disilybin, Arzneimittelforschung, 1975, 25, 392-393.
38. Siegers C P, Frühling A and Younes M, Influence of dithiocarb, (+)catechin and silybine on halothane hepatotoxicity in the hypoxic rat model, Acta Pharmacol Toxicol (Copenh), 1983, 53, 125-129.
39. Wu CG, Chamuleau RA, Bosch KS and Frederiks WM, Protective effect of silymarin on rat liver injury induced by ischemia, Virchows Arch B Cell Pathol Incl Mol Pathol, 1993, 64(5), 259-263.
40. Kropacova K, Misurova E and Hakova H, Protective and therapeutic effect of silymarin on the development of latent liver damage, Radiats Biol Radioecol, 1998, 38(3), 411-415.
41. Porokhniak LA, Drogovoz SM and Rogozhin BA, Action of hepatoprotective agents in a tetracycline lesion of the liver, Antibiot Med Biotekhnol, 1987, 32(4), 282-285.
42. Skakun NP and Stepanova NIu, Effectiveness of legalon and essentiale in a tetracycline-induced liver lesion, Antibiot Med Biotekhnol, 1986, 31(10), 781-784.
43. Das SK and Vasudevan DM, Drugs and nonalcoholic steatohepatitis, Indian J Pharmacol, 2006, 38(4), 238-242.
44. Sherlock S and Dooley J, Diseases of liver and biliary system, 11th Edn, Oxford: Blackwell Scientific Publications, 2002, pp. 322-56.
45. Munter K, Mayer D and Faulstich H, Characterization of a transporting system in rat hepatocytes: studies with competitive and non-competitive inhibitors of phalloidin transport, Biochem Biophys Acta, 1986, 860, 91-98.
46. Faulstich H, Jahn W and Wieland T, Silybin inhibition of amatoxin uptake in the perfused rat liver, Arzneimittelforschung, 1980, 30, 452-454.
47. Campos R, Garrido A, Guerra R and Valenzuela A, Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver, Planta Med, 1989, 55, 417-419.
48. Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM and Shear NH, Inducers of cytochrome P4502E1 enhances methotrexate-induced epatocytotoxicity. Clin Biochem, 1999, 32, 519-536.
49. von Schonfeld J, Weisbrod B and Muller MK, Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity, Cell Mol Life Sci, 1997, 53(11-12), 917-920.
50. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL and Strom SC, Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures, Drug Metab Dispos, 2000, 28(11), 1270-1273.
51. Deak G, Muzes G, Lang I, Nekam K, Gonzalez-Cabello R, Gergely P and Feher J, Effects of two bioflavonoids on certain cellular immune reactions in vitro, Acta Phsiol Hung. 1990, 76, 113-121.
52. Das SK and Vasudevan DM, Alcohol induced oxidative stress, Life Sci, 2007, 81(3), 177-187.
53. Lieber CS, New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments, Curr Gastroenterol Rep, 2004, 6(1), 60-65.
54. Arteel G, Marsano L, Mendez C, Bentley F and McClain CJ, Advances in alcoholic liver disease, Best Pract Res Clin Gastroenterol, 2003, 17(4), 625-647.
55. Das SK and Vasudevan DM, Protective effects of silymarin, a milk thistle (Silybium marianum) derivative on ethanol-induced oxidative stress in liver, Indian J Biochem Biophys, 2006, 43, 306-311.
56. van Pelt JF, Verslype C, Crabbe T, Zaman Z and Fevery J, Primary human hepatocytes are protected against prolonged and repeated exposure to ethanol by silibinin-dihemisuccinate, Alcohol Alcoholism, 2003, 38(5), 411-414.
57. Feher J, Deak G, Muzes G, Lang I, Niederland V, Nekam K and Karteszi M, Liver-protective action of silymarin therapy in chronic alcoholic liver diseases, Orv Hetil, 1989, 130(51), 2723-2727.
58. Stickel F, Seitz HK, Hahn EG and Schuppan D, Alcoholic liver disease-established treatment and new therapeutic approaches, Z Gastroenterol, 2003, 41(4), 333-342.
59. Pares A, Planas R, Torres M, Caballeria J, Viver JM, Acero D, Panes J, Rigau J, Santos J and Rodes J, Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial, J Hepatol, 1998, 28(4), 615-621.
60. Bunout D, Hirsch S, Petermann M, de la Maza M P, Silva G, Kelly M, Ugarte G and Iturriaga H, Controlled study of the effect of silymarin on alcoholic liver disease, Rev Med Chil, 1992, 120(12), 1370-1375.
61. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y and Lee DY, Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin, Gastroenterology, 2007, 132(5), 1925-1936.
62. Dehmlow C, Erhard J and de Groot H, Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin, Hepatology, 1996, 23(4), 749-754.
63. De La Puerta R, Martinez E, Bravo L and Ahumada MC, Effect of silymarin on different acute inflammation models and on leukocyte migration, J Pharm Pharmacol, 1996, 48(9), 968-970.
64. Fiebrich F and Koch H, Silymarin, an inhibitor of lipoxygenase, Experientia, 1979, 35(12), 1548-1560.
65. Meeran SM, Katiyar S, Elmets CA and Katiyar SK, Silymarin inhibits UV radiation-induced immunosuppression through augmentation of interleukin-12 in mice, Mol Cancer Ther, 2006, 5(7), 1660-1668.
66. Lee JS, Kim SG, Kim HK, Lee TH, Jeong YI, Lee CM, Yoon MS, Na YJ, Suh DS, Park NC, Choi IH, Kim GY, Choi YH, Chung HY and Park YM, Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells, J Cell Physiol, 2007, 210(2), 385-397.
67. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, Hong JS and Jeng KC, Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation, Eur J Neurosci, 2002, 16(11), 2103-2112.
68. Johnson VJ, He Q, Osuchowski MF and Sharma R P, Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses, Planta Med, 2003, 69(1), 44-49.
69. Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R and Tiegs G, Silibinin protects mice from T cell-dependent liver injury (small star, filled), J Hepatol, 2003, 39(3), 333-340.
70. Wilasrusmee C, Kittur S, Siddiqui J, Bruch D, Wilasrusmee S and Kittur DS, In vitro immunomodulatory effects of ten commonly used herbs on murine lymphocytes, J Altern Complement Med, 2002, 8(4), 467-475.
71. Dhanalakshmi S, Singh R P, Agarwal C and Agarwal R, Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis, Oncogene, 2002, 21(11), 1759-1767.
72. Manna SK, Mukhopadhyay A, Van NT and Aggarwal BB, Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis, J Immunol, 1999, 163(12), 6800-6809.
73. Dvorák Z, Vrzal R and Ulrichová J, Silybin and dehydrosilybin inhibit cytochrome P450 1A1 catalytic activity: a study in human keratinocytes and human hepatoma cells, Cell Biol Toxicol, 2006, 22(2), 81-90.
74. Varghese L, Agarwal C, Tyagi A, Singh RP and Agarwal R, Silibinin efficacy against human hepatocellular carcinoma, Clin Cancer Res, 2005, 11(23), 8441-8448.
75. McCarty M F, Potential utility of natural polyphenols for reversing fat-induced insulin resistance, Med Hypotheses, 2005, 64(3), 628-635.
76. Ortenberg EA, Zhikhareva AI and Byshevskii Ash, Impairment of lipid metabolism in the liver and its correction after exposure to ethanol and antitubercular agents, Vopr Med Khim, 1985, 31(6), 24-27.
77. Locher R, Suter PM, Weyhenmeyer R and Vetter W, Inhibitory action of silibinin on low density lipoprotein oxidation, Arzneimittelforschung, 1998, 48(3), 236-239.
78. Assuato G, Iemmolo RM, Strazzabosco M, Lirussi F, Deana R, Francesconi MA, Muraca M, Passera D, Fragasso A and Orlando R, Effect of Silibinin on biliary lipid composition. Experimental and clinical study, J Hepatol, 1991, 12(3), 290-295.
79. Schmidt KH, Muller U, Horer W and Braatz R, Changes in the pattern of microsomal fatty acids in rat liver after thermal injury and therapeutic intervention, Burns Incl Therm Inj, 1988, 14(1), 25-30.
80. Fuchs EC, Weyhenmeyer R and Weiner OH, Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts, Arzneimittelforschung, 1997, 47(12), 1383-1387.
81. He Q, Osuchowski MF, Johnson VJ and Sharma R P, Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: I induction of transforming growth factor beta1 and c-myc in liver with marginal effects on other genes, Planta Med, 2002, 68(8), 676-679.
82. Kittur S, Wilasrusmee S, Pedersen WA, Mattson M P, Straube-West K, Wilasrusmee C, Lubelt B and Kittur DS, Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture, J Mol Neurosci, 2002, 18(3), 265-269.
83. Zi X, Zhang J, Agarwal R and Pollak M, Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells, Cancer Res, 2000, 60(20), 5617-5620.
84. Singh R P, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C and Agarwal R, Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res, 2002, 62(11), 3063-3069.
85. Lahiri-Chatterjee M, Katiyar SK, Mohan RR and Agarwal R, A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumour promotion in the SENCAR mouse skin tumourigenesis model, Cancer Res, 1999, 59(3), 622-632.
86. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C and Agarwal R, Suppression of advanced human prostate tumour growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis, Cancer Epidemiol Biomarkers Prev, 2003, 12(9), 933-939.
87. Yanaida Y, Kohno H, Yoshida K, Hirose Y, Yamada Y, Mori H and Tanaka T, Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats, Carcinogenesis, 2002, 23(5), 787-794.
88. Bhatia N, Zhao J, Wolf DM and Agarwal R, Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin, Cancer Lett, 1999, 147(1-2), 77-84.
89. Katiyar SK, Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin, Int J Oncol, 2002, 21(6), 1213-1222.
90. Sharma Y, Agarwal C, Singh AK and Agarwal R, Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth and DNA synthesis in advanced human prostate carcinoma cells, Mol Carcinog, 2001, 30(4), 224-236.
91. Sharma G, Singh R P, Chan DC and Agarwal R, Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells, Anticancer Res, 2003, 23(3B), 2649-2655.
92. Zhu W, Zhang JS and Young CY, Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP, Carcinogenesis, 2001, 22(9), 1399-1403.
93. Tyagi A, Agarwal C and Agarwal R, Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention, Mol Cancer Ther, 2002, 1(7), 525-532.
94. Tyagi A, Agarwal C and Agarwal R, The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/ p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells, Cell Cycle, 2002, 1(2), 137-142.
95. Dhanalakshmi S, Agarwal P, Glode LM and Agarwal R, Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death, Int J Cancer, 2003, 106(5), 699-705.
96. Sharma Y, Agarwal C, Singh AK and Agarwal R, Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells, Mol Carcinog, 2001, 30(4), 224-236.
97. Yang SH, Lin JK, Chen WS and Chiu JH, Anti-angiogenic effect of silymarin on colon cancer LoVo cell line, J Surg Res, 2003, 113(1), 133-138.
98. Vinh PQ, Sugie S, Tanaka T, Hara A, Yamada Y, Katayama M, Deguchi T and Mori H, Chemopreventive effects of a flavonoid antioxidant silymarin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice, Jpn J Cancer Res, 2002, 93(1), 42-49.
99. Ramakrishnan G, Augustine TA, Jagan S, Vinodhkumar R and Devaki T, Effect of silymarin on N-nitrosodiethylamine induced hepatocarcinogenesis in rats, Exp Oncol, 2007, 29(1), 39-44.
100. Yoo HG, Jung SN, Hwang YS, Park JS, Kim MH, Jeong M, Ahn SJ, Ahn BW, Shin BA, Park RK and Jung YD, Involvement of NF-kappaB and caspases in silibinin-induced apoptosis of endothelial cells, Int J Mol Med, 2004, 13(1), 81-86.
101. Jacobs PB, Dennehy C, Ramirez G, Sapp J and Lawrence VA, Milk thistle for the treatment of liver disease: A systematic review and meta-analysis, Am J Med, 2002, 113, 506-515.
102. Sagar SM, Future directions for research on Silybum marianum for cancer patients, Integr Cancer Ther, 2007, 6(2), 166-173.
103. Sridar C, Goosen T, Kent UM, Williams JA and Hollenberg P F, Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltranferases. Drug Metab Dispos, 2004, 32, 587-594.
104. Zuber R, Modriansky M, Dvorak Z, Rohovsky P, Ulrichova J and Simanek V, Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities, Phytother Res, 2002, 16, 632-638.
105. Mayer KE, Myers RP and Lee SS, Silymarin treatment of viral hepatitis: a systematic review, J Viral Hepat, 2005, 12(6), 559-567.
106. Huber R, Futter I and Lüdtke R, Oral silymarin for chronic hepatitis C-a retrospective analysis comparing three dose regimens, Eur J Med Res, 2005, 10(2), 68-70.